14-3-3σ regulation of and interaction with YAP1 in acquired gemcitabine resistance via promoting ribonucleotide reductase expression

Li Qin, Zizheng Dong, Jian-Ting Zhang

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Gemcitabine is an important anticancer therapeutics approved for treatment of several human cancers including locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). Its clinical effectiveness, however, is hindered by existence of intrinsic and development of acquired resistances. Previously, it was found that 14-3-3σ expression associates with poor clinical outcome of PDAC patients. It was also found that 14-3-3σ expression is up-regulated in gemcitabine resistant PDAC cells and contributes to the acquired gemcitabine resistance. In this study, we investigated the molecular mechanism of 14-3-3σ function in gemcitabine resistance and found that 14-3-3σ up-regulates YAP1 expression and then binds to YAP1 to inhibit gemcitabine-induced caspase 8 activation and apoptosis. 14-3-3σ association with YAP1 up-regulates the expression of ribonucleotide reductase M1 and M2, which may mediate 14-3-3σ/YAP1 function in the acquired gemcitabine resistance. These findings suggest a possible role of YAP1 signaling in gemcitabine resistance.

Original languageEnglish (US)
Pages (from-to)17726-17736
Number of pages11
JournalOncotarget
Volume7
Issue number14
DOIs
StatePublished - 2016

Fingerprint

gemcitabine
Ribonucleotide Reductases
Adenocarcinoma
Up-Regulation
Caspase 8

Keywords

  • 14-3-3σ
  • Gemcitabine resistance
  • Gene expression
  • Ribonucleotide reductase
  • YAP1

ASJC Scopus subject areas

  • Oncology

Cite this

14-3-3σ regulation of and interaction with YAP1 in acquired gemcitabine resistance via promoting ribonucleotide reductase expression. / Qin, Li; Dong, Zizheng; Zhang, Jian-Ting.

In: Oncotarget, Vol. 7, No. 14, 2016, p. 17726-17736.

Research output: Contribution to journalArticle

@article{66f4b38e4d91473d8879683df36f32f5,
title = "14-3-3σ regulation of and interaction with YAP1 in acquired gemcitabine resistance via promoting ribonucleotide reductase expression",
abstract = "Gemcitabine is an important anticancer therapeutics approved for treatment of several human cancers including locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). Its clinical effectiveness, however, is hindered by existence of intrinsic and development of acquired resistances. Previously, it was found that 14-3-3σ expression associates with poor clinical outcome of PDAC patients. It was also found that 14-3-3σ expression is up-regulated in gemcitabine resistant PDAC cells and contributes to the acquired gemcitabine resistance. In this study, we investigated the molecular mechanism of 14-3-3σ function in gemcitabine resistance and found that 14-3-3σ up-regulates YAP1 expression and then binds to YAP1 to inhibit gemcitabine-induced caspase 8 activation and apoptosis. 14-3-3σ association with YAP1 up-regulates the expression of ribonucleotide reductase M1 and M2, which may mediate 14-3-3σ/YAP1 function in the acquired gemcitabine resistance. These findings suggest a possible role of YAP1 signaling in gemcitabine resistance.",
keywords = "14-3-3σ, Gemcitabine resistance, Gene expression, Ribonucleotide reductase, YAP1",
author = "Li Qin and Zizheng Dong and Jian-Ting Zhang",
year = "2016",
doi = "10.18632/oncotarget.7394",
language = "English (US)",
volume = "7",
pages = "17726--17736",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "14",

}

TY - JOUR

T1 - 14-3-3σ regulation of and interaction with YAP1 in acquired gemcitabine resistance via promoting ribonucleotide reductase expression

AU - Qin, Li

AU - Dong, Zizheng

AU - Zhang, Jian-Ting

PY - 2016

Y1 - 2016

N2 - Gemcitabine is an important anticancer therapeutics approved for treatment of several human cancers including locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). Its clinical effectiveness, however, is hindered by existence of intrinsic and development of acquired resistances. Previously, it was found that 14-3-3σ expression associates with poor clinical outcome of PDAC patients. It was also found that 14-3-3σ expression is up-regulated in gemcitabine resistant PDAC cells and contributes to the acquired gemcitabine resistance. In this study, we investigated the molecular mechanism of 14-3-3σ function in gemcitabine resistance and found that 14-3-3σ up-regulates YAP1 expression and then binds to YAP1 to inhibit gemcitabine-induced caspase 8 activation and apoptosis. 14-3-3σ association with YAP1 up-regulates the expression of ribonucleotide reductase M1 and M2, which may mediate 14-3-3σ/YAP1 function in the acquired gemcitabine resistance. These findings suggest a possible role of YAP1 signaling in gemcitabine resistance.

AB - Gemcitabine is an important anticancer therapeutics approved for treatment of several human cancers including locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). Its clinical effectiveness, however, is hindered by existence of intrinsic and development of acquired resistances. Previously, it was found that 14-3-3σ expression associates with poor clinical outcome of PDAC patients. It was also found that 14-3-3σ expression is up-regulated in gemcitabine resistant PDAC cells and contributes to the acquired gemcitabine resistance. In this study, we investigated the molecular mechanism of 14-3-3σ function in gemcitabine resistance and found that 14-3-3σ up-regulates YAP1 expression and then binds to YAP1 to inhibit gemcitabine-induced caspase 8 activation and apoptosis. 14-3-3σ association with YAP1 up-regulates the expression of ribonucleotide reductase M1 and M2, which may mediate 14-3-3σ/YAP1 function in the acquired gemcitabine resistance. These findings suggest a possible role of YAP1 signaling in gemcitabine resistance.

KW - 14-3-3σ

KW - Gemcitabine resistance

KW - Gene expression

KW - Ribonucleotide reductase

KW - YAP1

UR - http://www.scopus.com/inward/record.url?scp=84975504881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975504881&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.7394

DO - 10.18632/oncotarget.7394

M3 - Article

C2 - 26894857

AN - SCOPUS:84975504881

VL - 7

SP - 17726

EP - 17736

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 14

ER -